Base Year
Historical Year
Forecast Year
The global albumin market value in 2023 was USD 5.63 billion and is anticipated to grow at a CAGR of 6.20% during the forecast period of 2024-2032, driven by the growing demand for albumin-based drug formulations across the globe. The global albumin market size is anticipated to reach a value of USD 9.67 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Albumin is the most abundant plasma protein in adult humans, representing 50% of the total protein content of the plasma. The protein has a half-life of 21 days, with a concentration ranging from 35 to 59 g/L in the blood plasma. Albumin is synthesized by the liver at the rate of 10-15 grams per day. It has approximately 100 variant forms and plays an important role in maintaining the oncotic pressure to prevent the leaking of fluids into the extravascular space.
Albumin plays several physiological roles. It is accountable for maintaining 80% of the colloid osmotic pressure. A decrease in the level of serum albumin causes hypoalbuminemia, which is one of the most prevalent disorders In hospitalized and critically ill patients. Hypoalbuminemia has a prevalence rate of 70% in elderly hospitalized patients. Thus, the rising incidence of hypoalbuminemia is one of the key factors driving the albumin market growth.
The market is further boosted by the rising liver and cardiovascular disorders, which makes individuals prone to a low albumin levels in the body. In addition, the therapeutic and non-therapeutic applications of human serum albumin are propelling the market demand.
Technological Developments Expediating Albumin-Based Drug Delivery System
Albumin has become a popular delivery carrier for hydrophobic drugs due to advancements in nanotechnology. The surge in clinical applications is expected to boost the albumin market share in the forecast period. Owing to its unique chemical structure, albumin allows effective interaction with many drugs and protects them from elimination in vivo. In May 2023 , reverse QTY (rQTY) code was utilized to design amphiphilic human serum albumin (HAS) proteins, which resolved the problem of protein denaturation at the time of drug loading. Additionally, the HAS rQTY variants exhibited superior biological activities like tumor cell-targeting as compared to the denatured HAS nanoparticles. Such technological advancements in the drug development sector are bolstering the demand for albumin in the pharmaceutical industry.
Rise in Funding and Investment to Meet Albumin Market Demand
The pharmacokinetic and pharmacodynamic profile of albumin makes it an effective drug carrier. To exploit its versatility as a protein delivery vehicle, there has been increased funding and investment in the albumin market. In December 2023 , an Indian biopharmaceutical startup, PlasmaGen Biosciences raised around USD 27 million via equity funding to accelerate the growth of blood plasma-based products such as albumin. The company received major financing from Artian Investments (an investment management firm based in the United Kingdom) and other prominent investors.
Another major investment boosting the albumin market value was witnessed when SK Plasma, a South Korean developer of plasma-derived medicine, received USD 50 million from the Indonesia Investment Authority (INA), a government-owned sovereign wealth fund in October 2023. The funds will be used to build a plasma fractionation plant for manufacturing blood products such as albumin and immunoglobulin. Expected to be built by 2025, the facility is projected to process a million liters of raw plasma every year. The growing investments in the albumin market are anticipated to increase the market size in the coming years.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Product
Market Breakup by Application
Market Breakup by End User
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
In North America, the market growth of albumin is driven by the rising research and development activities for expanding the clinical applications of human, bovine, and recombinant serum albumin. Technological advancements in protein purification and molecular separation technology are anticipated to boost market growth.
Europe holds a significant albumin market share, owing to the presence of top healthcare companies in the region. Moreover, the rising focus of government on the development of albumin-derived pharmaceuticals is propelling market growth. In June 2023, the health authority in the United Kingdom, the Medicines and Healthcare Products Regulatory Agency (MHRA) lifted the ban on the use of blood plasma from donors of the United Kingdom to derive albumin. The authorization to use UK donor plasma to manufacture albumin treatments is expected to aid in the expansion of the albumin market in the region.
The expansion of manufacturing capacities and capabilities by the leading healthcare companies to accommodate the growing demand for albumin is one of the major market trends. In June 2023, Thermo Fisher Scientific, a biotechnology company based in the United States developed a ‘Biologics Manufacturing Facility’ covering an area of 1.5 million square feet in Switzerland. Thermo Fischer Scientific, along with their strategic partner CSL Limited (a global biotechnology company) will use the facility to produce Idelvion, a next-generation hemophilia product having recombinant albumin as an essential component, among other things. The growing demand for albumin in the development of drugs is expected to increase the albumin market size in the forecast period.
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 5.63 billion in 2023 driven by the growing demand for albumin-based drug delivery systems across the globe.
The market is anticipated to grow at a CAGR of 6.20% during the forecast period of 2024-2032, likely to reach a market value of USD 9.67 billion by 2032.
Advancements in nanotechnology for drug development, along with improvements in protein purification and molecular technologies are contributing to the increasing the market demand.
The surge in funding and investments is one of the major trends driving the albumin market. In December 2023, PlasmaGen Biosciences raised around USD 27 million via equity funding to accelerate the growth of its blood plasma-based products including albumin.
Based on the application type, the market is divided into drug delivery, therapeutics, vaccine ingredients, and culture media diagnostics.
The products in the market include human serum albumin, recombinant albumin, and bovine serum albumin.
Major end users in the market include hospitals, clinics, pharmaceutical as well as biotechnology industry, and research institutes.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
Key players involved in the market are Albumedix, Albumin Therapeutics, LLC, Biotest AG, CSL, Grifols, S.A., HiMedia Labortatories, Invitria, Medxbio Pte Ltd., Octapharma AG, RayBiotech, Inc., SeraCare, Merck KGaA, Takeda Pharmaceutical Company Limited, Kedrion S.p.A., and Aspira.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share